Status:
RECRUITING
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Lead Sponsor:
Barbara Ann Karmanos Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Brain and Central Nervous System Tumors
Chronic Myeloproliferative Disorders
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment a...
Detailed Description
OBJECTIVES: Primary * Evaluate the use of 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) positron emission tomography (PET) imaging to measure tumor proliferation and the DNA synthetic pathway (thymidine...
Eligibility Criteria
DISEASE CHARACTERISTICS:
-
Meets one of the following criteria:
- Histologically confirmed solid tumor or hematologic malignancy
- Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging
PATIENT CHARACTERISTICS:
- Able to lie still in the PET scanner
- Girth and weight must be suitable to enter the gantry
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
- Not specified
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
End Date :
May 1 2028
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00935090
Start Date
September 1 2009
End Date
May 1 2028
Last Update
July 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-1379